Sun Pharma Q4 FY26: Sales up 13.6% to ₹1,45,598 crore, Net Profit at ₹27,140 crore
Sun Pharma reported Q4 FY26 sales of ₹1,45,598 crore, up 13.6%, and net profit of ₹27,140 crore. Full-year FY26 sales were ₹5,82,000 crore, with a 16.1% rise in EBITDA to ₹1,77,314 crore. The company declared a total dividend of ₹16 per share for FY26. Innovative Medicines sales grew 20.1% in Q4, while India sales rose 14.8%.
The results reflect significant year-on-year growth in sales and profits, alongside strategic updates on acquisitions and future guidance, which are material to investors.
The company reported strong sales growth and increased profits, along with a healthy dividend payout and positive outlook for the next fiscal year.
Sun Pharmaceutical Industries Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. For Q4 FY26, consolidated sales were ₹1,45,598 million (₹1,45,598 crore), a growth of 13.6% compared to Q4 FY25. Gross margin stood at 80.8%, and EBITDA was ₹39,542 million, an increase of 6.4%. Reported net profit after tax for the quarter was ₹27,140 million, while adjusted net profit was ₹27,507 million. Earnings per share were ₹11.31.
For the full year FY26, sales reached ₹582,000 million (₹582,000 crore), a growth of 11.9%. EBITDA was ₹1,77,314 million, a growth of 16.1%, with an EBITDA margin of 30.3%. Adjusted net profit for the full year was ₹1,24,015 million.
The Board approved a final dividend of ₹5 per share, making the total dividend for FY26 ₹16 per share, same as the previous year. The company's net cash position remained strong at $3.2 billion.
The Global Innovative Medicines business reported sales of US$354 million in Q4 FY26, up 20.1%, and US$1,420 million for the full year FY26, up 16.8%. India formulations sales grew 14.8% in Q4 FY26 to ₹48,359 million and 14% for the full year to ₹1,92,904 million. The US business reported sales of US$459 million in Q4 FY26, a decline of 1.1%, and US$1.9 billion for the full year FY26. Emerging markets formulations revenues were US$306 million in Q4 FY26, up 17.4%. Rest of the World formulation revenues were US$220 million in Q4 FY26, up 10%.
The company expects high single-digit consolidated top-line growth for FY27 and plans to invest 6% to 7% of sales in R&D for FY27. The acquisition of Organon & Company is progressing, with regulatory filings underway and expected completion in Q4 FY27.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.